Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
TG Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-daily oral TGR-1202 in combination with once-daily oral Imbruvica ibrutinib in about 60 patients. TG Therapeu...